| For: | Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World J Gastroenterol 2013; 19(31): 5051-5060 [PMID: 23964138 DOI: 10.3748/wjg.v19.i31.5051] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i31/5051.htm |
| Number | Citing Articles |
| 1 |
David W. Greening, Sze Ting Lee, Hong Ji, Richard J. Simpson, Angela Rigopoulos, Carmel Murone, Catherine Fang, Sylvia Gong, Graeme O’Keefe, Andrew M. Scott. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget 2015; 6(35) doi: 10.18632/oncotarget.6241
|
| 2 |
Aubrey L. Miller, Patrick L. Garcia, Karina J. Yoon. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research 2020; 155 doi: 10.1016/j.phrs.2020.104740
|
| 3 |
Claudia W K Wu, Madeleine Reid, Simon Leedham, Rashid N Lui. The emerging era of personalized medicine in advanced colorectal cancer. Journal of Gastroenterology and Hepatology 2022; 37(8) doi: 10.1111/jgh.15937
|
| 4 |
|
| 5 |
M. Tampellini, A. La Salvia, G. V. Scagliotti. Novel investigational therapies for treating biliary tract carcinoma. Expert Opinion on Investigational Drugs 2016; 25(12) doi: 10.1080/13543784.2016.1252330
|
| 6 |
Kiminori Yanagisawa, Masamitsu Konno, Hao Liu, Shinji Irie, Tsunekazu Mizushima, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi, Michiya Matsusaki, Hideshi Ishii. A Four-Dimensional Organoid System to Visualize Cancer Cell Vascular Invasion. Biology 2020; 9(11) doi: 10.3390/biology9110361
|
| 7 |
Seyed Mohammadreza Bolandi, Zohreh Abdolmaleki, Mohammad-Ali Assarehzadegan. Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity. Inflammopharmacology 2021; 29(3) doi: 10.1007/s10787-021-00798-8
|
| 8 |
Javier Sánchez Ramírez, Mónica Bequet-Romero, Yanelys Morera Díaz, Francisco Hernández-Bernal, Ana de la Torre Santos, Katty-Hind Selman-Housein Bernal, Yenima Martín Bauta, Cimara H. Bermúdez Badell, Miladys Limonta Fernández, Marta Ayala Avila. Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors. Heliyon 2018; 4(11) doi: 10.1016/j.heliyon.2018.e00906
|
| 9 |
Keiko Akahane, Katsuyuki Shirai, Masaru Wakatsuki, Kazunari Ogawa, Kyosuke Minato, Kohei Hamamoto, Satoru Takahashi, Koichi Suzuki, Jun Takahashi, Toshiki Rikiyama, Keita Matsumoto, Hirosato Mashima. Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy. Clinical Case Reports 2020; 8(5) doi: 10.1002/ccr3.2751
|
| 10 |
Yu Zhong Peng, Li Jun Yang, Hang Hong Lo, Betty Yuen Kwan Law, Vincent Kam Wai Wong. New Nanomaterials and Techniques for Tumor-targeted Systems. 2020; doi: 10.1007/978-981-15-5159-8_6
|
| 11 |
Deepali Wanode, Deweshri Nandurkar, Rohini Palekar, Kumud Bhendarkar, Pramod Khedekar. VEGF/VEGFR: A Novel Therapy Target in Cancer. Current Cancer Therapy Reviews 2026; 22(5) doi: 10.2174/0115733947341681241209082508
|
| 12 |
Lydia A. Dan, Salem Werdyani, Jingxiong Xu, Konstantin Shestopaloff, Angela Hyde, Elizabeth Dicks, Ban Younghusband, Jane Green, Patrick Parfrey, Wei Xu, Sevtap Savas. No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients. Cancer Medicine 2016; 5(9) doi: 10.1002/cam4.796
|
| 13 |
Anupam Bishayee, Keith Block. A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead. Seminars in Cancer Biology 2015; 35 doi: 10.1016/j.semcancer.2015.08.002
|
| 14 |
Eirini Panoilia, Emilie Schindler, Epaminontas Samantas, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Christodoulou, George P. Patrinos, Lena E. Friberg, Gregory Sivolapenko. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology 2015; 75(4) doi: 10.1007/s00280-015-2701-3
|
| 15 |
Harish Kumar, Anusuya Bhattacharyya, Phulen Sarma. Pharmacological Approaches in Cancer Treatment. 2027; doi: 10.1016/B978-0-443-38307-6.00011-9
|
| 16 |
Y. Nancy You, Karin M. Hardiman, Andrea Bafford, Vitaliy Poylin, Todd D. Francone, Kurt Davis, Ian M. Paquette, Scott R. Steele, Daniel L. Feingold. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. Diseases of the Colon & Rectum 2020; 63(9) doi: 10.1097/DCR.0000000000001762
|
| 17 |
Daniela S. Ardelean, Michelle Letarte. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Frontiers in Genetics 2015; 6 doi: 10.3389/fgene.2015.00035
|
| 18 |
Louise M. Harkness, Anthony W. Ashton, Janette K. Burgess. Asthma is not only an airway disease, but also a vascular disease. Pharmacology & Therapeutics 2015; 148 doi: 10.1016/j.pharmthera.2014.11.010
|
| 19 |
Tao You, Jian Chen, Yuesheng Zhu, Na Shan, Zejun Gao, Yao Shen, Yaojun Yu. Novel preparation of pH-responsive hydrogel with chitosan-based microbeads for targeted oral delivery of bevacizumab to enhanced apoptosis in azoxymethane-induced colorectal cancer: cellular and in vivo mice models. Drug Delivery and Translational Research 2026; 16(2) doi: 10.1007/s13346-025-01928-3
|
| 20 |
Alexandre Filippello, Jack Porcheron, Jean Philippe Klein, Michèle Cottier, Gabriele Barabino. Affinity of Indocyanine Green in the Detection of Colorectal Peritoneal Carcinomatosis. Surgical Innovation 2017; 24(2) doi: 10.1177/1553350616681897
|
| 21 |
Yu Wang, Cheng Chen, Xin Xiao, Yajing Kang, Jinhan He, Ana Beloqui, Yining Xu. Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation. Advanced Drug Delivery Reviews 2026; 228 doi: 10.1016/j.addr.2025.115741
|
| 22 |
R. Sunitha, S. Madhavi Latha, M. Pavani, D. Durga Siva Prasad, Shaik Inthiyaz. Medicinal Herbs for Treating Colorectal Cancer – A Comprehensive Review. Asian Journal of Pharmaceutical Research 2025; doi: 10.52711/2231-5691.2025.00032
|
| 23 |
Sooraj Srirangadhamu Gopu, Rushad Patell, Erik J. Uhlmann, Rafael A. Vega, Brian J. Carney. Therapeutic Plasma Exchange for Removal of Bevacizumab: A Case Series. Journal of Clinical Apheresis 2026; 41(4) doi: 10.1002/jca.70166
|
| 24 |
Omid Rahbar Farzam, Niloofar Mehran, Farzaneh Bilan, Ehsan Aghajani, Reza Dabbaghipour, Ghazale Asemani Shahgoli, Behzad Baradaran. Nanoparticles for imaging-guided photothermal therapy of colorectal cancer. Heliyon 2023; 9(11) doi: 10.1016/j.heliyon.2023.e21334
|
| 25 |
Ke Li, Jieru Yang, Ying Peng, Huiwen Zheng, Zhizhan Fu, Meiying Li, Wenhu Zhou, Guofeng Yu. Advances in metal ion–mediated macromolecular drug delivery. International Journal of Pharmaceutics 2026; 689 doi: 10.1016/j.ijpharm.2025.126501
|
| 26 |
Adrien Guilloteau, Michal Abrahamowicz, Olayide Boussari, Valérie Jooste, Thomas Aparicio, Catherine Quantin, Karine Le Malicot, Christine Binquet. Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. BMC Medical Research Methodology 2021; 21(1) doi: 10.1186/s12874-020-01202-9
|
| 27 |
Zahra Monzavi Chaleshtori, Sanaz Darash, Sarvenaz Parsa, Elahe Orak Sarkani, Motahareh Taghizadeh, Omid Vakili. MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer. Clinica Chimica Acta 2025; 577 doi: 10.1016/j.cca.2025.120472
|
| 28 |
Toshiaki Yoshimoto, Kozo Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Mitsuo Shimada. Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab. Annals of Gastroenterological Surgery 2020; 4(2) doi: 10.1002/ags3.12312
|
| 29 |
Wael Shehta, Fatimah Agili, Basant Farag, Shaker Youssif, Samar J Almehmadi, Sherin M Elfeky, Samar El-Kalyoubi.
Synthesis and
In Vitro
Study of pyrimidine–phthalimide Hybrids As VEGFR2 Inhibitors With Antiproliferative Activity
. Future Medicinal Chemistry 2023; 15(8) doi: 10.4155/fmc-2023-0025
|
| 30 |
Aikaterini-Eftychia Micha, Kyriakos Psarras, Odysseas Ouroumidis, Evangelia Siska, Efthymia Vlachaki, Aristotelis Lymperopoulos, Nikolaos Symeonidis, Christina Nikolaidou, Ioannis Venizelos, George Koliakos, Theodoros E. Pavlidis. A Time Course of Bevacizumab (Anti-VEGF) Effect on Rat Peritoneum: Relations Between Antiadhesive Action and Fibrin Regulation Enzymes. Surgical Innovation 2017; 24(6) doi: 10.1177/1553350617729510
|
| 31 |
Isao Otsuka. Cutaneous Metastases in Ovarian Cancer. Cancers 2019; 11(9) doi: 10.3390/cancers11091292
|
| 32 |
Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares. Advances in Cancer Treatment. 2021; doi: 10.1007/978-3-030-68334-4_5
|
| 33 |
N. Giribabu, P.V. Rao, N. Salleh. Nanoarchitectonics for Smart Delivery and Drug Targeting. 2016; doi: 10.1016/B978-0-323-47347-7.00025-2
|
| 34 |
Marina Palmhof, Stephanie Lohmann, Dustin Schulte, Gesa Stute, Natalie Wagner, H. Burkhard Dick, Stephanie C. Joachim. Fewer Functional Deficits and Reduced Cell Death after Ranibizumab Treatment in a Retinal Ischemia Model. International Journal of Molecular Sciences 2018; 19(6) doi: 10.3390/ijms19061636
|
| 35 |
Shaocheng Zeng, Huangying Deng, Hanzhi Dong, Chunye Huang, Ruiwen Ruan, Xiaofeng Dai, Jianping Xiong, Jun Deng, Yangyang Yao. A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. Discover Oncology 2026; 17(1) doi: 10.1007/s12672-026-04459-6
|
| 36 |
Ugur Uyeturk, Adnan Gucuk, Tulin Firat, Eray Kemahli, Aysel Kukner, Mehmet Emin Ozyalvacli. Effect of Mitomycin, Bevacizumab, and 5-Fluorouracil to Inhibit Urethral Fibrosis in a Rabbit Model. Journal of Endourology 2014; 28(11) doi: 10.1089/end.2014.0420
|
| 37 |
Jorge Pablo Grondona. Extreme Hepatic Surgery and Other Strategies. 2017; doi: 10.1007/978-3-319-13896-1_6
|
| 38 |
Rowan Ives, Kyobin Hwang. The Diverse Roles of Monoclonal Antibodies in Cancer Immunotherapy and Their Relative Effectiveness: A Literature Review. Undergraduate Research in Natural and Clinical Science and Technology Journal 2022; 6 doi: 10.26685/urncst.342
|
| 39 |
Adam Barsouk, Prashanth Rawla, Andreas V. Hadjinicolaou, John Sukumar Aluru, Alexander Barsouk. Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. Medical Sciences 2019; 7(10) doi: 10.3390/medsci7100100
|
| 40 |
Lu Qi, Ying Zhang, Wenjuan Zhang, Yiqing Wang, Yue Han, Yanqing Ding. The inhibition of colorectal cancer growth by the natural product macrocarpal I. Free Radical Biology and Medicine 2021; 162 doi: 10.1016/j.freeradbiomed.2020.10.317
|
| 41 |
Apostolos Papachristos, Eleni Karatza, Haralabos Kalofonos, Gregory Sivolapenko. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences 2020; 21(11) doi: 10.3390/ijms21113753
|
| 42 |
Shreyas Joshi, Shreya Pandey, Kartik Adake, Kedar Ahire. Microbial Biofilms and Cancer - Part A. Progress in Molecular Biology and Translational Science 2026; 224 doi: 10.1016/bs.pmbts.2026.07.001
|
| 43 |
Su Woong Yoo, Gyungseok Oh, Abdul Mohaimen Safi, Soonjoo Hwang, Young-Seok Seo, Kyung-Hwa Lee, Young L. Kim, Euiheon Chung. Endoscopic non-ablative fractional laser therapy in an orthotopic colon tumour model. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-19792-2
|
| 44 |
Adeleh Sahebnasagh, Seyed Mohammad Nabavi, Hamid Reza Khayat Kashani, Safieh Aghaabdollahian, Solomon Habtemariam, Aysa Rezabakhsh. Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients. International Immunopharmacology 2021; 101 doi: 10.1016/j.intimp.2021.108257
|
| 45 |
Md Tanjim Alam, Mishfak A. M. Mansoor, Sarah A. Ashiqueali, Pawel Golusinski, Ewelina Golusinska-Kardach, Joanna K. Strzelczyk, Blazej Rubis, Wojciech Golusinski, Michal M. Masternak. The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy. Cancers 2025; 17(24) doi: 10.3390/cancers17244024
|
| 46 |
Isao Otsuka. Cutaneous Metastasis after Surgery, Injury, Lymphadenopathy, and Peritonitis: Possible Mechanisms. International Journal of Molecular Sciences 2019; 20(13) doi: 10.3390/ijms20133286
|
| 47 |
Mohammed Abdul-Latif, Katherine Townsend, Charles Dearman, Kai-Keen Shiu, Khurum Khan. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews 2020; 88 doi: 10.1016/j.ctrv.2020.102030
|
| 48 |
Chuan-Fang Pan, Xi Zhang, Jing-Wen Wang, Tao Yang, Linda L. D. Zhong, Ke-Ping Shen. Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.512598
|
| 49 |
Penki V.S. Sashankh, Dorothy Priyanka Dorairaj, Jia-Ying Chen, Yu-Lan Chang, Kuldeep Chand, Ramasamy Karvembu, Ching-Ming Chien, Sodio C.N. Hsu. Synthesis, in silico and in vitro studies of piperazinyl thiourea derivatives as apoptosis inducer for the treatment of colorectal carcinoma. Journal of Molecular Structure 2022; 1262 doi: 10.1016/j.molstruc.2022.133086
|
| 50 |
. 2021; doi: 10.70675/b2792726z4114z4d43zae17zda1aeba02aa9
|
| 51 |
Fusun Ozmen, Tevfik Tolga Şahin, M. Mahir Ozmen. Current Adjuvant Therapeutic Approaches for Pancreatic Cancer. Advances in Therapy 2015; 32(1) doi: 10.1007/s12325-015-0177-5
|
| 52 |
Souvik Roy, Zui Pan, Naif Abu Qarnayn, Mesfer Alajmi, Ali Alatawi, Asma Alghamdi, Ibrahem Alshaoosh, Zahra Asiri, Berlinda Batista, Shreshtha Chaturvedi, Olusola Dehinsilu, Hussein Edduweh, Rodina El-Adawy, Emran Hossen, Bardia Mojra, Jashmon Rana. A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer. Journal of Mathematical Biology 2024; 88(2) doi: 10.1007/s00285-023-02033-0
|
| 53 |
Jae Hyun Kim, Seun Ja Park. Target Therapy in Unresectable or Metastatic Colorectal Cancer. The Korean Journal of Gastroenterology 2016; 68(6) doi: 10.4166/kjg.2016.68.6.303
|
| 54 |
Chien-Chih Yeh, Li-Jane Shih, Junn-Liang Chang, Yi-Wei Tsuei, Chang-Chieh Wu, Cheng-Wen Hsiao, Chih-Pin Chuu, Yung-Hsi Kao. Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40862-6
|
| 55 |
Athanasios Patsalias, Zuzana Kozovska. Personalized medicine: Stem cells in colorectal cancer treatment. Biomedicine & Pharmacotherapy 2021; 141 doi: 10.1016/j.biopha.2021.111821
|
| 56 |
Cindy B. Yeoh, Kathleen J. Lee, Elizabeth F. Rieth, Renee Mapes, Anna V. Tchoudovskaia, Gregory W. Fischer, Luis E. Tollinche. COVID-19 in the Cancer Patient. Anesthesia & Analgesia 2020; 131(1) doi: 10.1213/ANE.0000000000004884
|
| 57 |
Timothy Johanssen, Laura McVeigh, Sara Erridge, Geoffrey Higgins, Joelle Straehla, Margaret Frame, Tero Aittokallio, Neil O. Carragher, Daniel Ebner. Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Frontiers in Oncology 2023; 12 doi: 10.3389/fonc.2022.1075559
|
| 58 |
Mauo-Ying Bien, Ming-Ping Wu, Wei-Lin Chen, Chi-Li Chung, Muniyan Sakthivel. VEGF Correlates with Inflammation and Fibrosis in Tuberculous Pleural Effusion. The Scientific World Journal 2015; 2015(1) doi: 10.1155/2015/417124
|
| 59 |
De-cong Sun, Yan Shi, Yan-rong Wang, Yao Lv, Huan Yan, Hui Mao, Zhi-kuan Wang, Zhi-yong Wu, Wei-wei Shi, Guang-hai Dai.
KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-14669-2
|
| 60 |
Saúl Redondo-Blanco, Javier Fernández, Ignacio Gutiérrez-del-Río, Claudio J. Villar, Felipe Lombó. New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00109
|
| 61 |
Christopher Fowell, Robert Jones, Hiroshi Nishikawa, Andrew Monaghan. Arteriovenous malformations of the head and neck: current concepts in management. British Journal of Oral and Maxillofacial Surgery 2016; 54(5) doi: 10.1016/j.bjoms.2016.01.034
|
| 62 |
Ghasem Noorkhajavi, Armin Banakholdi, Amirhosein Torabi, Amirreza Zoghi, Effat Iranijam, Elham Safarzadeh. Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment. Cancer Cell International 2025; 25(1) doi: 10.1186/s12935-025-04039-8
|
| 63 |
Jeroen A. C. M. Goos, Erienne M. V. de Cuba, Veerle M. H. Coupé, Begoña Diosdado, Pien M. Delis-Van Diemen, Cemile Karga, Jeroen A. M. Beliën, C. Willemien Menke-Van der Houven van Oordt, Albert A. Geldof, Gerrit A. Meijer, Otto S. Hoekstra, Remond J. A. Fijneman. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Annals of Surgery 2016; 263(1) doi: 10.1097/SLA.0000000000001109
|
| 64 |
Sara Charmsaz, Andrew M. Scott, Andrew W. Boyd. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Experimental Hematology 2017; 54 doi: 10.1016/j.exphem.2017.07.003
|
| 65 |
Elham Rostami, Olivera Casar-Borota, Olafur Gudjonsson. Adult Craniopharyngiomas. 2020; doi: 10.1007/978-3-030-41176-3_12
|
| 66 |
Zhiyong Wang, Jiaqi Li, Jinjin Guo, Pei Wei. Direct antitumor activity of bevacizumab: an overlooked mechanism?. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1394878
|
| 67 |
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, Yu Xiang, Pedro Gutierrez‐Castrellon, Xuelei Ma. Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions. MedComm 2022; 3(3) doi: 10.1002/mco2.154
|
| 68 |
Samuel Lee, Deirdre J. Cohen. Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. Expert Opinion on Pharmacotherapy 2019; 20(3) doi: 10.1080/14656566.2018.1551881
|
| 69 |
Siddharth J. Modi, Vithal M. Kulkarni. Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. Medicine in Drug Discovery 2019; 2 doi: 10.1016/j.medidd.2019.100009
|
| 70 |
Yawen Wu, Jie Zhang, Guanghao Li, Li Wang, Yajing Zhao, Baibing Zheng, Fanfeng Lin, Li Xie. Exosomal miR-320d promotes angiogenesis and colorectal cancer metastasis via targeting GNAI1 to affect the JAK2/STAT3 signaling pathway. Cell Death & Disease 2024; 15(12) doi: 10.1038/s41419-024-07297-y
|
| 71 |
William Torén, Daniel Ansari, Roland Andersson. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0715-8
|
| 72 |
Liu-qing Yang, Ru-yi Li, Xi-yan Yang, Qian-fei Cui, Fei-yun Wang, Guo-qiang Lin, Jian-ge Zhang. Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00565
|
| 73 |
Pir S Mahar, Sohail Bukhari, Ayisha Shakeel, Abdul Sami Memon, Tauseef Mahmood. Immediate Rise in Intraocular Pressure After First-Time Intravitreal Injection of Bevacizumab. Cureus 2023; doi: 10.7759/cureus.38916
|
| 74 |
Seon Ae Roh, In Ja Park, Yong Sik Yoon, Yi Hong Kwon, Jin Hwa Chung, Tae Won Kim, Dong Hyung Cho, Byung Ho Lim, Seon Kyu Kim, Seon Young Kim, Yong Sung Kim, Jin Cheon Kim. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology 2016; 142(8) doi: 10.1007/s00432-016-2177-5
|
| 75 |
Christoph Schulz, Volker Heinemann, Kathrin Heinrich, Michael Haas, Julian W. Holch, Alessia Fraccaroli, Swantje Held, Jobst C. von Einem, Dominik P. Modest, Ludwig Fischer von Weikersthal, Frank Kullmann, Markus Moehler, Werner Scheithauer, Andreas Jung, Sebastian Stintzing. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. Anti-Cancer Drugs 2020; 31(8) doi: 10.1097/CAD.0000000000000965
|
| 76 |
. 2015; doi: 10.70675/9c91ffcbz2afez438ezaea2z0a9ddd1c7b5f
|
| 77 |
Efstathios T. Pavlidis, Theodoros E. Pavlidis. Current Molecular and Genetic Aspects of Pancreatic Cancer, the Role of Metastasis Associated Proteins (MTA): A Review. Journal of Investigative Surgery 2018; 31(1) doi: 10.1080/08941939.2016.1269854
|
| 78 |
Miao Zhou, Wenyan Wang, Jiahao Weng, Zhikun Lai. A Review on Probable Causes of Cardiotoxicity Caused by Common Cancer Drugs and the Role of Traditional Chinese Medicine in Prevention and Treatment. Pharmacogenomics and Personalized Medicine 2023; doi: 10.2147/PGPM.S427585
|
| 79 |
Ferran Medina-Jover, Antoni Riera-Mestre, Francesc Viñals. Rethinking growth factors: the case of BMP9 during vessel maturation. Vascular Biology 2022; 4(1) doi: 10.1530/VB-21-0019
|
| 80 |
R. Sunitha, S. Madhavi Latha, M. Pavani, D. Durga Siva Prasad, Shaik Inthiyaz. Medicinal Herbs for Treating Colorectal Cancer – A Comprehensive Review. Research Journal of Pharmacognosy and Phytochemistry 2025; doi: 10.52711/0975-4385.2025.00026
|
| 81 |
S. Takada, Y. Hoshino, H. Ito, Y. Masugi, T. Terauchi, K. Endo, M. Kimata, J. Furukawa, H. Shinozaki, K. Kobayashi, Y. Ogata. Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. Japanese Journal of Clinical Oncology 2015; 45(3) doi: 10.1093/jjco/hyu206
|
| 82 |
Furong Kou, Jifang Gong, Yan Li, Jian Li, Xiaotian Zhang, Jie Li, Lin Shen. Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites. Journal of International Medical Research 2021; 49(2) doi: 10.1177/0300060520986664
|
| 83 |
Christian Seebauer, Fares Hanafieh, Jan Wolff, Hans‐Robert Metelmann, Marcus Vollmer. Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. British Journal of Clinical Pharmacology 2025; 91(9) doi: 10.1002/bcp.70073
|
| 84 |
Alexandre Dubrac, Gael Genet, Roxana Ola, Feng Zhang, Laurence Pibouin-Fragner, Jinah Han, Jiasheng Zhang, Jean-Léon Thomas, Alain Chedotal, Martin A. Schwartz, Anne Eichmann. Targeting NCK-Mediated Endothelial Cell Front-Rear Polarity Inhibits Neovascularization. Circulation 2016; 133(4) doi: 10.1161/CIRCULATIONAHA.115.017537
|
| 85 |
A. Roger, M.-L. Sigal, P. Bagan, C. Sin, P. Bilan, B. Dakhil, C. Fargeas, J.-C. Couffinhal, E. Mahé. Ulcères des membres inférieurs développés sous inhibiteurs de tyrosine kinase (sunitinib, nilotinib). Annales de Dermatologie et de Vénéréologie 2017; 144(1) doi: 10.1016/j.annder.2016.06.009
|
| 86 |
Asghar Fallah, Hamid Reza Heidari, Behzad Bradaran, Mahsa Mollapour Sisakht, Sirous Zeinali, Ommoleila Molavi. A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment. Life Sciences 2019; 239 doi: 10.1016/j.lfs.2019.117018
|
| 87 |
Jeroen A.C.M. Goos, Veerle M.H. Coupé, Mark A. van de Wiel, Begoña Diosdado, Pien M. Delis-Van Diemen, Annemieke C. Hiemstra, Erienne M.V. de Cuba, Jeroen A.M. Beliën, C. Willemien Menke - van der Houven van Oordt, Albert A. Geldof, Gerrit A. Meijer, Otto S. Hoekstra, Remond J.A. Fijneman. A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9. Oncotarget 2016; 7(2) doi: 10.18632/oncotarget.6188
|
| 88 |
Özgür AKKAYA, Eyüp AYDOĞAN. The dose-dependent antiangiogenic potential of apixaban: an experimental outlook. Acta Medica Alanya 2022; 6(2) doi: 10.30565/medalanya.1129978
|
| 89 |
Long-Zhuan Huang, Ya-Qing Chen, Hang-Ye Gu, Yong Chen. Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer. Frontiers in Public Health 2024; 12 doi: 10.3389/fpubh.2024.1465898
|
| 90 |
Brian Stagg, Hironori Uehara, Nathan Lambert, Ruju Rai, Isha Gupta, Bryce Radmall, Taylor Bates, Balamurali Ambati. Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth. Cancers 2014; 6(4) doi: 10.3390/cancers6042330
|
| 91 |
Nesrin Gariballa, Bassam R. Ali. Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGFβ Signaling Pathway: Future Therapeutic Perspectives. Frontiers in Molecular Biosciences 2020; 7 doi: 10.3389/fmolb.2020.575608
|